A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma
Study of ATX-101 in Patients with Dedifferentiated Liposarcoma (LPS) and Leiomyosarcoma (LMS)
Sponsor: APIM Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAT7079
U.S. Govt. ID: NCT05116683
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the effectiveness of a new investigational drug, ATX-101, for the treatment of dedifferentiated liposarcoma and leiomyosarcoma. ATX-101 is an intravenous (IV) drug which blocks the interaction of a protein called PCNA with a number of stress response proteins. These interactions are thought to be important for cancer cell survival and growth. ATX-101 may disrupt these interactions and therefore help treat the cancer. In this study, all patients will receive the same treatment. Most of the exams, tests, and procedures you will have are part of the usual approach to medical care for your condition. However, some additional tests or procedures may be performed, and other tests may be performed more frequently than usual.
This study is closed
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with dedifferentiated liposarcoma (LPS) or leiomyosarcoma (LMS)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162